ISRG AI Stock Analysis – Buy, Hold, or Avoid?
Intuitive Surgical, Inc. (ISRG)
Fundamentals
Intuitive Surgical (ISRG) demonstrates robust financial health marked by consistent revenue and earnings growth, strong profitability, and a proven ability to surpass market expectations. While premium valuation persists, the company’s underlying operational excellence, scalable business model, and dominant market leadership in robotic-assisted surgery support continued long-term growth potential. Investors should remain alert to competitive and regulatory risks despite these strong fundamentals.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
18.76% YoY
Q4 2025
Net Income
15.91% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9B | 2.5B | 2.4B | 2.3B | 2.4B | 2.0B | 2.0B | 1.9B |
| Revenue Growth YoY | +18.76% | +22.91% | +21.40% | +19.19% | +25.16% | +16.88% | +14.47% | +11.46% |
| Net Income | 794.8M | 704.4M | 658.4M | 698.4M | 685.7M | 565.1M | 526.9M | 544.9M |
| Net Income Growth YoY | +15.91% | +24.65% | +24.96% | +28.17% | +13.11% | +35.94% | +25.21% | +53.36% |
| EPS | $2.24 | $1.98 | $1.84 | $1.95 | $1.92 | $1.59 | $1.48 | $1.54 |
| EPS Growth YoY | +16.67% | +24.53% | +24.32% | +26.62% | +11.63% | +34.75% | +23.33% | +52.48% |
Profitability Metrics
Technical Analysis
ISRG is currently in a strong downtrend characterized by price trading below key moving averages with an active death cross. Momentum indicators signal bearish pressure despite a strong ADX confirming the strength of the prevailing downtrend. Traders should exercise caution as the stock remains in a pronounced declining phase without clear bullish reversal signals.
No extreme reading
Price in downtrend
Strong trend active
50 below 200 - bearish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Intuitive Surgical (ISRG) demonstrates robust financial health marked by consistent revenue and earnings growth, strong profitability, and a proven ability to surpass market expectations. While premium valuation persists, the company’s underlying operational excellence, scalable business model, and dominant market leadership in robotic-assisted surgery support continued long-term growth potential. Investors should remain alert to competitive and regulatory risks despite these strong fundamentals.
Latest Earnings
Q4 2025 Earnings (Dec 31, 2025)
Earnings Per Share (EPS)
Actual
$2.53
Estimated
$2.27
Surprise
+$0.26
Surprise %
+11.45%
Revenue
Actual
$2.87B
Estimated
$2.76B
Surprise
+$103.57M
Surprise %
+3.75%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $2.53 | $2.40 | $2.19 | $1.81 | $2.21 | $1.84 | $1.78 | $1.50 |
| EPS (Estimated) | $2.27 | $1.99 | $1.93 | $1.74 | $1.76 | $1.63 | $1.54 | $1.41 |
| EPS Surprise | +$0.26 | +$0.41 | +$0.26 | +$0.07 | +$0.45 | +$0.21 | +$0.24 | +$0.09 |
| % Diff | +11.5% | +20.6% | +13.5% | +4.0% | +25.6% | +12.9% | +15.6% | +6.4% |
| Revenue | ||||||||
| Revenue (Actual) | $2.87B | $2.51B | $2.44B | $2.25B | $2.41B | $2.04B | $2.01B | $1.89B |
| Revenue (Estimated) | $2.76B | $2.41B | $2.35B | $2.19B | $2.25B | $2.01B | $1.97B | $1.87B |
| Revenue Surprise | +$103.57M | +$98.71M | +$88.75M | +$67.59M | +$164.64M | +$32.62M | +$38.31M | +$20.39M |
| % Diff | +3.7% | +4.1% | +3.8% | +3.1% | +7.3% | +1.6% | +1.9% | +1.1% |
Valuation
Intuitive Surgical (ISRG) currently trades at a premium valuation with strong financial health and impressive profitability metrics, reflecting investor confidence in its market leadership within the medical instruments sector. While the valuation multiples are elevated compared to peers, robust revenue and earnings growth support a cautious optimism. Technical indicators are mixed, suggesting a consolidation phase, and market sentiment remains cautiously bullish despite concerns over high multiples.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 63.22 | 56.60 | 73.97 | 63.38 | 67.82 | 77.33 | 73.48 | 64.04 |
| Price to Sales | 70.13 | 63.66 | 79.84 | 78.57 | 77.08 | 85.76 | 77.05 | 73.83 |
| Price to Book | 11.28 | 9.42 | 10.92 | 10.35 | 11.32 | 11.22 | 10.53 | 10.00 |
| Enterprise Value to EBITDA | 182.40 | 170.36 | 212.98 | 242.68 | 214.22 | 248.57 | 223.57 | 236.30 |
| Enterprise Value to Revenue | 69.06 | 62.54 | 78.45 | 77.43 | 76.30 | 84.58 | 75.54 | 72.33 |
Sentiment & Analyst Ratings
Intuitive Surgical (ISRG) sentiment is moderately positive with cautious optimism prevailing among analysts and investors despite recent share price declines. Analysts largely affirm a buy stance driven by strong procedural growth, a robust recurring revenue model, and promising new product rollouts, while concerns over margin pressures and slower growth moderate enthusiasm.
Analyst Recommendations
Risk Assessment
Intuitive Surgical exhibits a strong financial position with robust liquidity and minimal debt, supporting its operational flexibility amid margin pressures and competitive challenges. While its leading market share and innovative platforms provide growth avenues, risks from tariff impacts, regional competition, and slower growth in key markets temper near-term outlook. Investors face a moderate overall risk profile balanced by solid earnings growth and market position.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 4.87 | 4.73 | 5.17 | 4.98 | 4.07 | 4.30 | 5.15 | 5.55 |
| Quick Ratio | 3.96 | 3.74 | 4.18 | 3.97 | 3.22 | 3.42 | 4.22 | 4.61 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Debt-to-Assets | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Liquidity Assessment
Current Ratio: 4.87(Strong)
Quick Ratio: 3.96(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 0.02(Low)
Debt-to-Assets: 0.01(Low)
The company has conservative debt levels, indicating low financial risk and strong long-term solvency.
Frequently Asked Questions about ISRG
AI Answers: Common Questions About ISRG
Get AI-powered answers to the questions investors ask most about Intuitive Surgical, Inc.
ISRG is not an ideal buy for short-term traders given its current technical downtrend and premium P/E of 57.33, but long-term investors may find value in its dominant market position and consistent growth. The stock is trading about 25% below its 52-week high, with analyst targets implying significant upside if fundamentals persist. Entry is best timed after a technical base or on further weakness.
If you are a short-term trader, selling or reducing exposure may be prudent due to the ongoing downtrend and lack of bullish reversal signals. Long-term holders with conviction in ISRG’s fundamentals can hold through volatility, as the investment thesis remains intact and the company continues to deliver strong results.
The biggest risks are margin compression from tariffs and higher manufacturing costs, increased competition (especially in China), and slower growth in key international markets like Japan. Sentinel notes ISRG’s debt-to-equity is only 0.017 and current ratio is 4.87, so liquidity risk is low, but operational and regulatory risks remain.
Technical support is near $427.84, with resistance at $482 and $505. Analyst price targets average around $619, implying 33-37% upside from current levels, but near-term downside to the $428 level is possible if the downtrend persists.
ISRG is overvalued relative to peers, with a P/E ratio more than double the industry average and high EV/EBITDA and P/S multiples. While some contraction from historical peaks has occurred, the stock still trades at a significant growth premium, justified only by continued strong execution.
ISRG is fundamentally strong: 2025 revenue grew 20.5% YoY, net margins exceed 28%, ROE is 16-17%, and the company has a large, growing installed base with high-quality recurring revenue. Liquidity and balance sheet strength are best-in-class.
Technical analysis is bearish: ISRG is in a Stage 4 decline below all major moving averages, with a death cross and RSI at 35.9 (near oversold). No bullish reversal patterns are present, and the next support is at $427.84.
Key catalysts include upcoming earnings reports, new product launches (especially da Vinci 5 and Ion platform expansion), FDA clearances, and any acceleration in procedure growth or margin improvement. Watch for technical base formation as a signal for new entries.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.